AstraZeneca completes acquisition for North America tilt
Date added:
03/03/2015
BIOPHARMACUETICAL company AstraZeneca has acquired the rights to Actavis’ branded respiratory business in the US and Canada for an initial consideration of £380m ($600m). The company says the strategic transaction strengthens AstraZeneca’s respiratory franchise globally and builds on the acquisition of Almirall’s respiratory portfolion in 2014 by extending its development and commercialisation rights into the US for both Tudorza Pressair and Duaklir Genuair, treatments for chronic obstructive pulmonary diseas....
Back to all news